SOHO 2024
Age ≥65 years, arrhythmia, and cardiogenic shock were associated with a significantly higher rate of acute heart failure.
Liso-cel demonstrated clinical benefit and manageable safety, with low incidences of grade ≥3 CRS.
Length of venetoclax dosing and prior chemotherapy exposure were associated with prolonged hematological recovery.
Advertisement
The phase Ib/II FELIX trial found that obe-cel is effective for the treatment of relapsed or refractory adult B-cell ALL.
Fixed-duration ibrutinib plus venetoclax provides durable PFS in patients with CLL.
Ibrutinib provides significantly longer PFS and OS benefits in CLL when compared to chlorambucil.
Advertisement
Oral targeted inhibitors are a viable treatment for patients with CLL with severe renal dysfunction.
Switching rates within 60 days were lower for patients treated with zanubrutinib compared with acalabrutinib and ibrutinib.
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.
An expert on myelofibrosis comments on promising results from current trials and on the need for useful clinical biomarkers.
Anito-cel showed "robust" efficacy in patients with relapsed or refractory multiple myeloma.
Myeloma in remission did not appear to affect myocardial infarction outcomes, but did affect resource utilization.
The latest data update on teclistamab in multiple myeloma continues to support strong efficacy and durable response.
The addition of daratumumab improved the performance of VRd in patients with newly diagnosed multiple myeloma.
The phase III SIERRA trial compared Iomab-B-led allogeneic HSCT with conventional care in older patients with AML.
The prognostic significance of mNPM1 MRD is greatest in AML patients with concomitant FLT3-ITD.
Some interventions such as PARP inhibitors can cause adverse events, but others such as HSCT can benefit patients.
Sorafenib, a FLT3 inhibitor, led to significantly improved survival compared with placebo in patients with AML.
Brentuximab vedotin plus lenalidomide and rituximab combination showed promising efficacy and potential as bridging therapy.
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.